CUA Educational Content

Treatment Evolutions in Prostate Cancer: DNA Damage Response and the Therapeutic Rationale for PARP Inhibition

EDITORIAL COMMITTEE: Fred Saad, Neil Fleshner, Michael Boivin, Michael Kolinsky, Anil Kapoor

At the conclusion of this program, participants should be able to:

  • recognize the DNA damage response (DDR) gene mutations that are involved in prostate cancer, and their implications for therapy
  • integrate genetic testing for patients with prostate cancer into their clinical practice
  • describe the mechanism of action, efficacy, and safety of PARP inhibitors in order to employ these agents for the treatment of prostate cancer with DDR mutations
  • explain the timing, monitoring, and management of adverse events


This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

​This program has received financial support from Merck and AstraZeneca Canada.